SILO PHARMA, INC. Increase (Decrease) in Deferred Revenue
SILO PHARMA, INC. (SILO) reported Increase (Decrease) in Deferred Revenue of -$18.03 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2024-05-13
- SILO PHARMA, INC. increase (decrease) in deferred revenue for the quarter ending 2024-03-31 was -$18.03K.
- SILO PHARMA, INC. increase (decrease) in deferred revenue for the quarter ending 2023-12-31 was -$18.03K.
- SILO PHARMA, INC. increase (decrease) in deferred revenue for the quarter ending 2023-09-30 was -$18.02K.
- SILO PHARMA, INC. increase (decrease) in deferred revenue for the quarter ending 2023-06-30 was -$18.02K.
- SILO PHARMA, INC. increase (decrease) in deferred revenue for fiscal 2023 was -$72.10K.
- SILO PHARMA, INC. increase (decrease) in deferred revenue for fiscal 2022 was -$72.10K, a 115.06% decline from fiscal 2021.
- SILO PHARMA, INC. increase (decrease) in deferred revenue for fiscal 2021 was $478.74K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 3 month as first filed | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | -$18.03K 10-Q · filed 2024-05-13 | -$36.05K derived: sum of 2 quarters · filed 2024-05-13 | -$54.08K derived: sum of 3 quarters · filed 2024-05-13 | -$72.10K derived: sum of 4 quarters · filed 2024-05-13 | |
| 2023-12-31 | -$18.03K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$36.05K derived: sum of 2 quarters · filed 2024-03-25 | -$54.08K derived: sum of 3 quarters · filed 2024-03-25 | -$72.10K 10-K · filed 2024-03-25 | |
| 2023-09-30 | -$18.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$36.05K derived: sum of 2 quarters · filed 2023-11-13 | -$54.08K 10-Q · filed 2023-11-13 | -$72.10K derived: sum of 4 quarters · filed 2024-05-13 | |
| 2023-06-30 | -$18.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$36.05K 10-Q · filed 2023-08-11 | -$54.08K derived: sum of 3 quarters · filed 2024-05-13 | -$72.10K derived: sum of 4 quarters · filed 2024-05-13 | |
| 2023-03-31 | -$18.03K 10-Q · filed 2024-05-13 | -$18.02K 10-Q · filed 2023-05-12 | -$36.05K derived: sum of 2 quarters · filed 2024-05-13 | -$54.08K derived: sum of 3 quarters · filed 2024-05-13 | -$72.10K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$18.02K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$36.05K derived: sum of 2 quarters · filed 2024-03-25 | -$54.08K derived: sum of 3 quarters · filed 2024-03-25 | -$72.10K 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$18.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$36.05K derived: sum of 2 quarters · filed 2023-11-13 | -$54.08K 10-Q · filed 2023-11-13 | -$72.10K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$18.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$36.05K 10-Q · filed 2023-08-11 | -$54.08K derived: sum of 3 quarters · filed 2023-08-11 | -$72.10K derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | -$18.02K 10-Q · filed 2023-05-12 | -$36.05K derived: sum of 2 quarters · filed 2023-05-12 | -$54.08K derived: sum of 3 quarters · filed 2023-05-12 | -$22.10K derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | -$18.03K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$36.05K derived: sum of 2 quarters · filed 2023-03-24 | -$4.08K derived: sum of 3 quarters · filed 2023-03-24 | $478.74K 10-K · filed 2023-03-24 | |
| 2021-09-30 | -$18.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $13.95K derived: sum of 2 quarters · filed 2022-11-10 | $496.76K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $31.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $514.79K 10-Q · filed 2022-08-01 | |||
| 2021-03-31 | $482.81K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |